New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on October 9, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lilly Endowment Inc, a significant shareholder in Eli Lilly & Co, has recently sold 101,420 shares of the company’s stock. This transaction is valued at an impressive $86,234,295.
Recent Updates on LLY stock
Eli Lilly & Co. has announced updates on several clinical studies, which could potentially influence its stock performance. The company is leading a Phase 3 study on retatrutide and tirzepatide for metabolic dysfunction-associated steatotic liver disease, aiming to mitigate liver complications, with recruitment starting in 2025. Another Phase 3 study focuses on Orforglipron for stress urinary incontinence in overweight women, highlighting a significant unmet need. Additionally, a Phase 1 study, FiREBOLT, is evaluating LY4337713 for FAP-positive solid tumors, showcasing Eli Lilly’s commitment to innovative cancer treatments. The FRAmework-01 study is assessing LY4170156 for ovarian and related cancers, potentially offering new treatment avenues. Lastly, a completed Phase 1 study on bimagrumab and tirzepatide could enhance drug formulations. These developments may positively impact Eli Lilly’s stock by strengthening its pipeline and market position in competitive therapeutic areas.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly & Co’s overall stock score reflects strong financial performance and positive earnings call highlights, indicating robust growth prospects. However, high valuation and potential risks from leverage and cash flow management temper the outlook. The technical analysis suggests bullish momentum, but caution is advised due to overbought conditions.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: 10.20%
Average Trading Volume: 4,666,028
Technical Sentiment Signal: Strong Buy
Current Market Cap: $798.5B